Healthy work environments slash costs of workplace injuries and illnesses, study finds

The FDA is set­ting out to stream­line in­ter­na­tion­al reg­u­la­tions of gene ther­a­pies with a pi­lot pro­gram to re­view ap­pli­ca­tions along­side glob­al reg­u­la­to­ry part­ners, an agency

Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now. Mer­ck, the mak­er of the drug they’re try­ing to beat, is en­ter­ing the

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug